AVO:LSE-Advanced Oncotherapy plc (GBX)

COMMON STOCK | Medical Devices | LSE

Last Closing Price

GBX 30.50

Change

0.00 (0.00)%

Market Cap

GBX 0.09B

Volume

0.04M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Advanced Oncotherapy plc, together with its subsidiaries, engages in designing, assembling, selling, and maintaining proton-based radiotherapy systems for treatment of cancer. It is developing Linac Image Guided Hadron Technology, a proton therapy system for treating cancer. It has operations in the United Kingdom, Switzerland, and the United States. The company was formerly known as CareCapital Group plc and changed its name to Advanced Oncotherapy PLC in September 2012. Advanced Oncotherapy plc was founded in 1994 and is headquartered in London, the United Kingdom. Address: 4 Tenterden Street, London, United Kingdom, W1S 1TE

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-26 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SN:LSE Smith & Nephew plc

N/A

GBX13.11B 41.62 15.99
CREO:LSE Creo Medical Limited

N/A

GBX0.26B N/A N/A
MGP:LSE Medica Group Plc

N/A

GBX0.14B 28.44 14.00
IDH:LSE Immunodiagnostic Systems Holdi..

N/A

GBX0.07B 19.83 5.35
IHC:LSE Inspiration Healthcare Group p..

N/A

GBX0.04B 29.57 22.25
KMK:LSE Kromek Group plc

N/A

GBX0.04B N/A 19.23
MED:LSE Intelligent Ultrasound Group p..

N/A

GBX0.04B N/A N/A
LID:LSE LiDCO Group Plc

N/A

GBX0.02B N/A N/A
SUN:LSE Surgical Innovations Group plc

N/A

GBX0.02B N/A 82.45
DEMG:LSE Deltex Medical Group plc

N/A

GBX7.09M N/A 41.08

ETFs Containing AVO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -23.75% 25% F 28% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.75% 25% F 27% F
Trailing 12 Months  
Capital Gain -23.75% 33% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.75% 33% F 24% F
Trailing 5 Years  
Capital Gain -83.17% 20% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -83.17% 20% F 6% F
Average Annual (5 Year Horizon)  
Capital Gain -7.72% N/A N/A 16% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.72% N/A N/A 15% F
Risk Return Profile  
Volatility (Standard Deviation) 78.08% N/A N/A 14% F
Risk Adjusted Return -9.89% N/A N/A 23% F
Market Capitalization 0.09B 75% C 45% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.25 67% D+ 29% F
Price / Cash Flow Ratio -3.97 75% C 74% C
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -54.06% 17% F 10% F
Return on Invested Capital -41.74% 17% F 7% F
Return on Assets -15.17% 33% F 12% F
Debt to Equity Ratio 32.29% 57% F 52% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.13 25% F 26% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector